文献标引:张胜桃，隗佳，何培根.生物制剂在类风湿关节炎的临床应用[J/CD].中华临床医师杂志：电子版,2010,4(2):127-130.

参考文献:
[1]　Yazici Y，Shi N，John A. Utilization of biologic agents in rheumatoid arthritis in the United States：analysis of prescribing patterns in 16，752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis，2008，66（2）：77－85.[PubMed]
[2]　Donahue KE，Gartlehner G，Jonas DE，et al. Systematic review：comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med，2008，148（2）：124－134.[PubMed]
[3]　Alonso-Ruiz A，Pijoan JI，Ansuategui E，et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis：systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord，2008，9：52.[PubMed]
[4]　Goekoop-Ruiterman YP，de Vries-Bouwstra JK，Allaart CF，et al. Comparison of treatment strategies in early rheumatoid arthritis：a randomized trial. Ann Intern Med，2007，146（6）：406－415.[PubMed]
[5]　O′Dell JR. The BeSt way to treat early rheumatoid arthritis？Ann Intern Med，2007，146（6）：459－460.[PubMed]
[6]　Nurmohamed MT，Dijkmans BA. Are biologics more effective than classical disease-modifying antirheumatic drugs？Arthritis Res Ther，2008，10（5）：118.[PubMed]
[7]　Sfriso P，Salaffi F，Montecucco CM，et al. MonitorNet：the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. Reumatismo，2009，61（2）：132－139.[PubMed]
[8]　Atzeni F，Antivalle M，Pallavicini FB，et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev，2009，8（5）：431－437.[PubMed]
[9]　Alonso-Ruiz A，Pijoan JI，Ansuategui E，et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis：systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord，2008，9：52.[PubMed]
[10]　Kristensen LE，Christensen R，Bliddal H，et al. The number needed to treat for adalimumab，etanercept，and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis：a systematic literature review. Scand J Rheumatol，2007，36（6）：411－417.[PubMed]
[11]　Bongartz T，Sutton AJ，Sweeting MJ，et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies：systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA，2006，295（19）：2275－2285.[PubMed]
[12]　Westhovens R，Yocum D，Han J，et al. The safety of infliximab，combined with background treatments，among patients with rheumatoid arthritis and various comorbidities. Arthritis Rheum，2006，54（4）：1075－1086.[PubMed]